FutureWorld: peers
FutureWorld beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
FutureWorld: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | FutureWorldbase FWDG · 🇺🇸 US Percentile in Healthcare Percentile in USA | Actinium Pharmaceuticals, Inc. ATNM · 🇺🇸 US Percentile in Healthcare Percentile in USA | AIM ImmunoTech Inc. AIM · 🇺🇸 US Percentile in Healthcare Percentile in USA | iBio, Inc. IBIO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Inovio Pharmaceuticals, Inc. INO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Silo Pharma, Inc. SILO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Ainos, Inc. AIMD · 🇺🇸 US Percentile in Healthcare Percentile in USA | BullFrog AI Holdings, Inc. BFRG · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | —— | $48 MOct 30, 2026 · Market data3rd of 7 | $6 MOct 27, 2026 · Market data5th of 7 | $59 MOct 9, 2026 · Market data2nd of 7 | $144 MOct 30, 2026 · Market data1st of 7 | $3 MOct 5, 2026 · Market data7th of 7 | $6 MOct 26, 2026 · Market data6th of 7 | $9 MOct 29, 2026 · Market data4th of 7 | $9 M7 ranked |
| Revenue (Better neither way: ranked highest first) | $0 MFY2014 · SEC4th of 8 | $0 MFY2025 · SEC4th of 8 | $0 MFY2025 · SEC4th of 8 | $0 MFY2026 · SEC3rd of 8 | $0 MFY2025 · SEC7th of 8 | $0 MFY2025 · SEC7th of 8 | $0 MFY2025 · SEC1st of 8 | $0 MFY2025 · SEC1st of 8 | $0 M8 ranked |
| Net income (Higher is better) | $-2 MFY2014 · SEC1st of 8 | $-34 MFY2025 · SEC7th of 8 | $-14 MFY2025 · SEC4th of 8 | $-33 MFY2026 · SEC6th of 8 | $-85 MFY2025 · SEC8th of 8 | $-4 MFY2025 · SEC2nd of 8 | $-15 MFY2025 · SEC5th of 8 | $-7 MFY2025 · SEC3rd of 8 | $-14 M8 ranked |
| Employees (Better neither way: ranked highest first) | —— | 25March 25, 2026 · Profile3rd of 4 | —— | —— | 317As on 2021 · Profile1st of 4 | —— | 41December 31, 2025 · Profile2nd of 4 | 9December 31, 2025 · Profile4th of 4 | 334 ranked |
| Margins and returns | |||||||||
| Return on equity (Higher is better) | ———— | -167.0%FY2025 · SEC4th of 613th6th | ———— | -65.7%FY2026 · SEC1st of 635th15th | -183.5%FY2025 · SEC6th of 612th5th | -74.6%FY2025 · SEC2nd of 632nd14th | -128.0%FY2025 · SEC3rd of 619th8th | -183.1%FY2025 · SEC5th of 612th5th | -147.5%6 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | 534.6×price Oct 30, 2026 · Market data2nd of 698th100th | 71.0×price Oct 27, 2026 · Market data4th of 693rd97th | 591.6×price Oct 9, 2026 · Market data1st of 699th100th | ———— | 46.1×price Oct 5, 2026 · Market data6th of 690th97th | 51.1×price Oct 26, 2026 · Market data5th of 691st97th | 76.3×price Oct 29, 2026 · Market data3rd of 693rd98th | 73.7×6 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | 6.1×price Oct 30, 2026 · Market data1st of 673rd81st | ———— | 0.7×price Oct 9, 2026 · Market data5th of 612th11th | 6.0×price Oct 30, 2026 · Market data2nd of 672nd80th | 0.5×price Oct 5, 2026 · Market data6th of 67th7th | 0.8×price Oct 26, 2026 · Market data4th of 615th15th | 4.3×price Oct 29, 2026 · Market data3rd of 662nd73rd | 2.5×6 ranked |
| Free cash flow yield (Higher is better) | ———— | -51.3%price Oct 30, 2026 · Market data3rd of 518th7th | ———— | -40.2%price Oct 9, 2026 · Market data2nd of 521st9th | -61.6%price Oct 30, 2026 · Market data4th of 515th6th | ———— | -75.7%price Oct 26, 2026 · Market data5th of 511th4th | -10.0%price Oct 29, 2026 · Market data1st of 542nd21st | -51.3%5 ranked |
| Financial strength | |||||||||
| Interest cover (Higher is better) | ———— | ———— | -14.4×FY2025 · SEC1st of 337th18th | -702.8×FY2026 · SEC3rd of 33rd1st | ———— | -107.0×FY2025 · SEC2nd of 315th6th | ———— | ———— | -107.0×3 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 1 of 12FY2025 · Scorecard5th of 7 | 1 of 13FY2025 · Scorecard6th of 7 | 2 of 14FY2026 · Scorecard2nd of 7 | 2 of 13FY2025 · Scorecard1st of 7 | 2 of 14FY2025 · Scorecard2nd of 7 | 2 of 14FY2025 · Scorecard2nd of 7 | 1 of 13FY2025 · Scorecard6th of 7 | 14% passed7 ranked |
| Valuation checks (Higher is better) | —— | 0 of 3FY2025 · Scorecard4th of 7 | 0 of 4FY2025 · Scorecard4th of 7 | 1 of 5FY2026 · Scorecard2nd of 7 | 0 of 4FY2025 · Scorecard4th of 7 | 1 of 4FY2025 · Scorecard1st of 7 | 1 of 5FY2025 · Scorecard2nd of 7 | 0 of 5FY2025 · Scorecard4th of 7 | 0% passed7 ranked |
| Growth checks (Higher is better) | —— | 0 of 2FY2025 · Scorecard3rd of 7 | 1 of 3FY2025 · Scorecard2nd of 7 | 0 of 2FY2026 · Scorecard3rd of 7 | 1 of 2FY2025 · Scorecard1st of 7 | 0 of 2FY2025 · Scorecard3rd of 7 | 0 of 2FY2025 · Scorecard3rd of 7 | 0 of 1FY2025 · Scorecard3rd of 7 | 0% passed7 ranked |
| Profitability checks (Higher is better) | —— | 0 of 3FY2025 · Scorecard1st of 7 | 0 of 2FY2025 · Scorecard1st of 7 | 0 of 3FY2026 · Scorecard1st of 7 | 0 of 3FY2025 · Scorecard1st of 7 | 0 of 3FY2025 · Scorecard1st of 7 | 0 of 3FY2025 · Scorecard1st of 7 | 0 of 3FY2025 · Scorecard1st of 7 | 0% passed7 ranked |
| Financial health checks (Higher is better) | —— | 1 of 3FY2025 · Scorecard1st of 7 | 0 of 3FY2025 · Scorecard7th of 7 | 1 of 4FY2026 · Scorecard5th of 7 | 1 of 3FY2025 · Scorecard1st of 7 | 1 of 4FY2025 · Scorecard5th of 7 | 1 of 3FY2025 · Scorecard1st of 7 | 1 of 3FY2025 · Scorecard1st of 7 | 33% passed7 ranked |
| Shareholder returns checks (Higher is better) | —— | 0 of 1FY2025 · Scorecard1st of 6 | 0 of 1FY2025 · Scorecard1st of 6 | —— | 0 of 1FY2025 · Scorecard1st of 6 | 0 of 1FY2025 · Scorecard1st of 6 | 0 of 1FY2025 · Scorecard1st of 6 | 0 of 1FY2025 · Scorecard1st of 6 | 0% passed6 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 16.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 2.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 58.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 33.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 18.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 2.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 4.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 16.0%7 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 502026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 602026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 1112026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 132026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 152026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 247 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | -0.1 pp2026-Q2 against 2026-Q1 · 13F5th of 6 | +1.7 pp2026-Q2 against 2026-Q1 · 13F3rd of 6 | +14.9 pp2026-Q2 against 2026-Q1 · 13F1st of 6 | -13.7 pp2026-Q2 against 2026-Q1 · 13F6th of 6 | —— | +0.5 pp2026-Q2 against 2026-Q1 · 13F4th of 6 | +2.1 pp2026-Q2 against 2026-Q1 · 13F2nd of 6 | +1.1 pp6 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = FutureWorld: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Actinium Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; AIM ImmunoTech Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; iBio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Inovio Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Silo Pharma, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Ainos, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; BullFrog AI Holdings, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Return on equity#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Return on equity | In its sector | In its country |
|---|---|---|---|
| FutureWorld | — | — | — |
| Actinium Pharmaceuticals, Inc. | -167.0%FY2025 | 13th percentile in Healthcaremedian -36.9%, 977 companies | 6th percentile in USAmedian 4.8%, 3,580 companies |
| AIM ImmunoTech Inc. | — | — | — |
| iBio, Inc. | -65.7%FY2026 | 35th percentile in Healthcaremedian -36.9%, 977 companies | 15th percentile in USAmedian 4.8%, 3,580 companies |
| Inovio Pharmaceuticals, Inc. | -183.5%FY2025 | 12th percentile in Healthcaremedian -36.9%, 977 companies | 5th percentile in USAmedian 4.8%, 3,580 companies |
| Silo Pharma, Inc. | -74.6%FY2025 | 32nd percentile in Healthcaremedian -36.9%, 977 companies | 14th percentile in USAmedian 4.8%, 3,580 companies |
| Ainos, Inc. | -128.0%FY2025 | 19th percentile in Healthcaremedian -36.9%, 977 companies | 8th percentile in USAmedian 4.8%, 3,580 companies |
| BullFrog AI Holdings, Inc. | -183.1%FY2025 | 12th percentile in Healthcaremedian -36.9%, 977 companies | 5th percentile in USAmedian 4.8%, 3,580 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | FutureWorld | Actinium Pharmaceuticals, Inc. | AIM ImmunoTech Inc. | iBio, Inc. | Inovio Pharmaceuticals, Inc. | Silo Pharma, Inc. | Ainos, Inc. | BullFrog AI Holdings, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2026 | — | — | — | $0 MSEC | — | — | — | — |
| 2025 | — | $0 MSEC4th | $0 MSEC4th | $0 MSEC1st | $0 MSEC6th | $0 MSEC6th | $0 MSEC2nd | $0 MSEC2nd |
| 2024 | — | — | $0 MSEC3rd | $0 MSEC1st | $0 MSEC1st | $0 MSEC4th | — | — |
| 2023 | — | — | $0 MSEC2nd | — | $1 MSEC1st | $0 MSEC4th | $0 MSEC3rd | $0 MSEC5th |
| 2022 | — | $1 MSEC4th | $0 MSEC5th | $2 MSEC3rd | $10 MSEC1st | $0 MSEC6th | $4 MSEC2nd | $0 MSEC7th |
| 2021 | — | $1 MSEC2nd | $0 MSEC4th | $2 MSEC1st | — | — | $1 MSEC3rd | — |
| 2020 | — | — | $0 MSEC3rd | $2 MSEC2nd | $7 MSEC1st | $0 MSEC4th | $0 MSEC5th | — |
| 2019 | — | — | $0 MSEC3rd | $2 MSEC2nd | $4 MSEC1st | $0 MSEC4th | $0 MSEC5th | — |
| 2018 | — | — | $0 MSEC3rd | $0 MSEC2nd | $30 MSEC1st | — | $0 MSEC4th | — |
| 2017 | — | — | $0 MSEC2nd | $0 MSEC3rd | $42 MSEC1st | — | $0 MSEC4th | — |
| 2016 | — | — | $0 MSEC3rd | $1 MSEC2nd | $35 MSEC1st | — | — | — |
| 2015 | — | — | $0 MSEC3rd | $2 MSEC2nd | $41 MSEC1st | — | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of FutureWorld#
Companies of the same industry, within a hundred times its size (latest annual revenue), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Actinium Pharmaceuticals, Inc.ATNM · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $48 M (Oct 30, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- AIM ImmunoTech Inc.AIM · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $6 M (Oct 27, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- iBio, Inc.IBIO · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $59 M (Oct 9, 2026) · revenue $0 M (year to June 2026)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Inovio Pharmaceuticals, Inc.INO · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $144 M (Oct 30, 2026) · revenue $0 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Silo Pharma, Inc.SILO · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $3 M (Oct 5, 2026) · revenue $0 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Ainos, Inc.AIMD · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $6 M (Oct 26, 2026) · revenue $0 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- BullFrog AI Holdings, Inc.BFRG · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $9 M (Oct 29, 2026) · revenue $0 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Serina Therapeutics, Inc.SER · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $50 M (Oct 30, 2026) · revenue $0 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)+ Add
- VivoSim Labs, INC.VIVS · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $3 M (Oct 20, 2026) · revenue $0 M (year to March 2026)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)+ Add
- Connect Biopharma Holdings LimitedCNTB · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $54 M (Oct 30, 2026) · revenue $0 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Avalo Therapeutics, Inc.AVTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $430 M (Oct 30, 2026) · revenue $0 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)+ Add
- Zivo Bioscience Inc.ZIVO · 🇺🇸 USASame industry: Biotechnology · Similar size: $0 M revenue against $0 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $20 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2024)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.